Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Decreases By 65.8%

INVO Fertility, Inc (NASDAQ:IVF) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 260,114 shares, a decrease of 65.8% from the June 30th total of 760,242 shares. Currently, 14.6% of the shares of the company are short sold. Based on an average daily trading volume, of 358,678 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

INVO Fertility Price Performance

IVF stock traded down $0.06 on Monday, reaching $0.94. 82,677 shares of the company’s stock were exchanged, compared to its average volume of 1,687,274. The stock has a fifty day moving average of $1.45 and a 200-day moving average of $3.10. The firm has a market cap of $1.68 million, a PE ratio of -0.00 and a beta of 2.28. The company has a quick ratio of 0.87, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. INVO Fertility has a twelve month low of $0.91 and a twelve month high of $90.80.

INVO Fertility (NASDAQ:IVF) last released its earnings results on Monday, June 22nd. The company reported ($3.38) EPS for the quarter. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%. The business had revenue of $2.02 million during the quarter.

Institutional Trading of INVO Fertility

A hedge fund recently bought a new position in INVO Fertility stock. Citadel Advisors LLC bought a new stake in INVO Fertility, Inc (NASDAQ:IVF) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility at the end of the most recent quarter. 12.02% of the stock is owned by institutional investors and hedge funds.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.